ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 212

Utility of Mood Disorders Questionnaire in Fibromyalgia: Data from the Cleveland Clinic Fibromyalgia Registry

Carmen Gota1, Sahar Kaouk 2, Kinanah Yaseen 1, Nilamba Jhala 1 and William Wilke 3, 1Cleveland Clinic, Cleveland, OH, 2University of Dayton, Gates Mills, OH, 3Cleveland Clinic, Richmond Heights, OH

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: bipolar disorder and mood disorder questionnaire, fibromyalgia

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Fibromyalgia & Other Clinical Pain Syndromes Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with comorbid fibromyalgia syndrome (FMS) and bipolar disorder (BD) were found to have more severe FMS. The Mood disorders questionnaire (MDQ), a self-reported inventory of lifetime history of manic and hypomanic symptoms has been proposed as a screening tool for BD, but its specificity for BD has been controversial. We evaluated the relationship between MDQ and a history of self-reported prior clinical diagnosis of BD.

Methods: Consecutive patients diagnosed clinically with FMS were enrolled and demographic, socioeconomic and clinical data were collected. Patients completed the following standardized questionnaires; for depression PHQ-9 (patient health questionnaire), anxiety GAD-7 (generalized anxiety disorder questionnaire), disability HAQ-DI (health assessment questionnaire disability index), PDI (pain disability index), PSD (polysymptomatic distress scale/fibromyalgianess scale), WPI (widespread pain index), SS (symptom severity scale), FIQ (fibromyalgia impact questionnaire).

Results: We enrolled 430 patients with FMS who completed the MDQ and also reported a history of psychiatric evaluation, of which 118 (27.5%) had bipolar disorder by either MDQ or prior psychiatric diagnosis. The mean age was 43.3 (12.0), 89.3% female and 87.7% met the ACR 2010 criteria for FMS. The mean MDQ was 3.9 (3.3) and 20.9% had an MDQ >=7. A psychiatric diagnosis of BD was made in 59 (13.7%) of patients; 6.7% (29%) had a BD diagnosis by psychiatry and an MDQ of < 7. Thirty patients (7%) had a diagnosis of BD both by MDQ and psychiatry.  Correlation between MDQ and a past psychiatric diagnosis of BD was low, r= 0.293 (p< 0.005). The sensitivity of an MDQ ³7 for a prior diagnosis of BD was 42.4% and the specificity was 13.5%. Patients with MDQ³ 7 had significantly higher scores on depression and anxiety as well as higher fibromyalgianess, fibromyalgia severity and disability scores (Table 1). We performed three separate linear regression analyses to predict FMS severity measured by FIQ from depression (PHQ-9), anxiety (GAD-7) and bipolar disorder determined by MDQ, psychiatric diagnosis or both. Depression and anxiety but not a positive screen for BD either by MDQ , prior clinical diagnosis of BD or either, remained independent predictors of FIQ variance.

Conclusion: The utility of MDQ as a screening tool for BD in patients with FMS, as well as the impact of a psychiatric diagnosis of BD on FMS measures and severity, needs to be further evaluated. Nevertheless, patients with high MDQ scores seem to have more severe depressive and anxiety symptoms and score higher on FMS measures of severity and impact.


Table 1 for bipolar abstract

Table 1. Comparison between FMS patients with BD and those without BD diagnosed by MDQ, psychiatric diagnosis, or both


Table 2 for bipolar abstract

Table 2: Linear regression to predict FIQ variability from depression, -PHQ-9- anxiety -GAD-7- and bipolar disorder determined by either MDQ, psychiatric diagnosis or both


Disclosure: C. Gota, None; S. Kaouk, None; K. Yaseen, None; N. Jhala, None; W. Wilke, None.

To cite this abstract in AMA style:

Gota C, Kaouk S, Yaseen K, Jhala N, Wilke W. Utility of Mood Disorders Questionnaire in Fibromyalgia: Data from the Cleveland Clinic Fibromyalgia Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/utility-of-mood-disorders-questionnaire-in-fibromyalgia-data-from-the-cleveland-clinic-fibromyalgia-registry/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utility-of-mood-disorders-questionnaire-in-fibromyalgia-data-from-the-cleveland-clinic-fibromyalgia-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology